Critically ill pediatric patients with persistently low stimulated TNF-α production have been shown to be more likely to acquire life-threatening infections, and importantly, treatment with immune-adjuvant GM-CSF was shown to cause a rapid improvement in stimulated TNF-α production that was associated with prevention of nosocomial infections [4, 14]. The gene discussed is CSF2; the disease is infection.